Business Services Industry

Lexington, Mass., Drug Maker's Stock Plummets on Poor Antibiotic Performance.

Knight Ridder/Tribune Business News, January, 2002

By Naomi Aoki, The Boston Globe Knight Ridder/Tribune Business News

Jan. 18--Shares of Cubist Pharmaceuticals Inc. fell 46 percent yesterday on news that the company's antibiotic failed to prove it was as effective as a rival drug in treating a severe form of pneumonia.

The Lexington company's stock closed at $17.02 a share on the Nasdaq Stock Market in unusually heavy trading, down $14.73 from the previous day's close.

The stock began a rapid descent after Wednesday's close when the company announced that results from a pneumonia study of its antibiotic, Cidecin, fell short of the study's goals.

The news was particularly devastating because Cidecin would be Cubist's first marketed product. The company had planned to seek...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement